Office of Technology Transfer – University of Michigan

Treatment of Rheumatoid Arthritis and Other Erosive Bone Conditions with Peptidomimetics

Technology #5313

Questions about this technology? Ask a Technology Manager

Download Printable PDF

Categories
Researchers
Joseph Holoshitz
Managed By
Ed Pagani
Associate Director, Health Technologies 734-763-3558
Patent Protection
US Patent Pending
US Patent Pending

Rheumatoid arthritis represents a growing unmet clinical need

Rheumatoid arthritis (RA) afflicts approximately 2.5 million people in the US, with over 50,000,000 suffering from the disease globally.   There is no cure for RA. Currently available treatments can alleviate some symptoms and modestly slow disease progression; however these therapies fail to provide relief and adequately slow joint damage in all patients.  New therapies are needed which can effectively correct the cellular signaling pathway aberrations that cause RA. Such therapies have the potential to inhibit disease progression, and could possibly be curative.

Cyclic small peptide drugs discovered for RA

Research into RA pathogenesis has led to the discovery of a new class of potential RA therapeutics by University of Michigan researchers. This class of therapeutics consists of cyclized small peptides which inhibit the detrimental signaling cascades that are associated with RA disease progression. These compounds show efficacy in an in vivo mouse model of RA. Moreover, these novel drugs also inhibit osteoclast differentiation and activation, suggesting therapeutic potential for osteoporosis and other bone erosive conditions.

Applications

  • new therapeutic for RA
  • potential therapeutics for osteoporosis, erosive bone diseases

Advantages

  • potent small peptide compounds with picomolar EC50
  • multiple related compounds show efficacy